Program
:
Young Investigator Meeting (YIM) : YIM Session I: Clinical & Translational Research
YIM Session I: Clinical & Translational Research
Ibrutinib lead-in followed by venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
Incidence of Richter transformation in patients with chronic lymphocytic leukemia (CLL): a cohort study evaluating different therapeutic eras
Prevalence and clinical impact of clonal hematopoiesis in chronic lymphocytic leukemia
Preclinical efficacy of the BCL2i venetoclax combined with MEKi cobimetinib or SYKi entospletinib in BTKi-refractory CLL patients harboring BTK mutations
Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
The Gene Expression Landscape of BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia Exposed by Shallow Depth RNA Sequencing
Young Investigator Meeting (YIM) : YIM Session II: Translational & Basic Research
YIM Session II: Translational & Basic Research
TLR9 signaling is a potential tumor escape mechanism following B-cell receptor targeted treatments in subsets of
BH3 Profiling Identifies Anti-Apoptotic Dependencies and Therapeutic Vulnerabilities in Primary Richter Transformation (RT) Cells and in a Genetically-Engineered Murine Model of RT
LYN kinase activity and its regulator CSK are key players in CLL supporting macrophages
Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition
Role of G protein-coupled receptor kinase 2 (GRK2) in the localization and activation of leukemic cells
Rps15-S138F mutation results in translational errors underlying onset of chronic lymphocytic leukemia
Young Investigator Meeting (YIM) : YIM Session III: Guided Poster Walk with Coffee & Tea
YIM Session III: Guided Poster Walk with Coffee & Tea
Adaptation of chronic lymphocytic leukemia to ibrutinib is L mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway
Combined therapy of endocytosis inhibitors and a novel glycoengineered anti-ROR1 antibody to enhance antibody-dependent cellular cytotoxicity (ADCC) against chronic lymphocytic leukemi
A Comparative Study of Different Macrophage Feeder Systems for the Support of Chronic Lymphocytic Leukemia Survival
CAR T cells generated from CLL patients are characterized by determinants of immune dysfunction that may be positively modulated by treatment with targeted agents
Venetoclax resistant cells are sensitive to anti-CD20 V monoclonal antibodies.
Utility of the international chronic lymphocytic leukemia prognostic index in front-line treatment with targeted drugs